Sanofi

FDA issues approval for Sanofi’s Enjaymo treatment for patients with CAD

The US FDA has approved Sanofi’s Enjaymo (sutimlimab-jome) for the treatment of adults diagnosed with the rare blood disorder, cold agglutinin disease (CAD). ... Bill Sibold, Sanofi’s executive vice president and head of Specialty Care said: “Until

Sanofi unveils new corporate brand and logo

Sanofi has unveiled its new corporate brand image, which reflects the organisation’s ongoing transformation and modernisation. ... Looking ahead, Sanofi aims to continue with its goals of providing healthcare innovation and furthering its company

Sanofi and Regeneron’s Dupixent receives second positive phase 3 trial results

The latest news from Sanofi Genzyme and Regeneron Pharmaceuticals shared positive results from the second phase 3 for Dupixent (dupilumab), a medicine the companies developed to target chronic inflammatory skin diseases. ... Dupixent is a jointly

Sanofi and Exscientia agree on a deal worth up to $5.2bn for AI-driven therapies

According to the terms detailed in the agreement, Sanofi will pay Exscientia an upfront cash payment of $100m. ... Alongside this, Sanofi will take responsibility for preclinical and clinical development, manufacturing and further commercialisation.

FDA rejects Takeda’s Eohilia after delays

The rejection by the FDA potentially clears the way for Sanofi’s Dupixent (dupilumab), which received breakthrough therapy designation in EoE back in September 2020. ... In October 2021, Sanofi announced results of a second phase 3 trial for Dupixent

[ Previous 5 results ] 4 5 6 7 8 9 10 11 12 13 [ Next 5 results ]